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Needle Tract Implantation after
Percutaneous Interventional Procedures
in Hepatocellular Carcinomas: Lessons
Learned from a 10-year Experience
Percutaneous interventional procedures under image guidance, such as biop-
sy, ethanol injection therapy, and radiofrequency ablation play important roles in
the management of hepatocellular carcinomas. Although uncommon, the proce-
dures may result in tumor implantation along the needle tract, which is a major
delayed complication. Implanted tumors usually appear as one or a few, round or
oval-shaped, enhancing nodules along the needle tract on CT, from the intraperi-
toneum through the intercostal or abdominal muscles to the subcutaneous or
cutaneous tissues. Radiologists should understand the mechanisms and risk fac-
tors of needle tract implantation, minimize this complication, and also pay atten-
tion to the presence of implanted tumors along the needle tract during follow-up.
ercutaneous interventional procedures under image guidance play
important roles in the management of hepatocellular carcinomas (HCCs).
Three common percutaneous interventional procedures are used to
manage HCCs: percutaneous biopsy for pathologic diagnosis, percutaneous ethanol
injection therapy (PEIT), and percutaneous radiofrequency (RF) ablation. These are
usually performed under guidance of ultrasonography, which allows monitoring of the
procedures in real-time. Ultrasonography-guidance helps save time relative to other
modalities such as computed tomography (CT) or magnetic resonance imaging (MRI).
A variety of immediate or delayed major complications may occur during or after
the procedures (1). All of these procedures require insertion of sharp, long needles into
the liver parenchyma and tumors, which may cause injury to internal structures and
result in hepatic arterial pseudoaneurysm, intrahepatic or subcapsular hematoma,
hemoperitoneum, biloma, bile peritonitis, pneumothorax, or infection. The major
biopsy complication rates and the associated mortality rates are low, 0.05% 0.18%
and 0.006% 0.031%, respectively. In both PEIT and RF ablation, the major compli-
cation rates and mortality rates are less than 2% and up to 0.1%, respectively (1-5).
However, implantation of tumors along the pathway of the needle can occur during
long-term follow-up.
We present the proposed mechanisms, risk factors, frequency, and spectrum of CT
findings of needle tract implantation and growth patterns after three common percuta-
neous interventional procedures, biopsy, PEIT, and RF ablation for HCCs. We also
address the lessons learned from our 10-year experience in minimizing tumor implan-
tation.
Mechanisms and Risk Factors of Needle Tract Implantation
During percutaneous interventional procedures, viable cancer cells that adhere to
the needle can be disseminated along the needle tract during removal. In addition,
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Pblood or fluid refluxing back along the tract may carry
cancer cells into the peritoneal cavity or to the surface of
the skin. Cancer cells may be forced into the tract by a
sudden increase in intratumoral pressure, as commonly
occurs during RF ablation. Cancer cells have a tendency to
spontaneously spread, mainly due to low adhesiveness,
low stromal content, and enzyme release following
interventional procedures. An experimental study showed
that 1,000 10,000 tumor cells could be seeded from a
solid tumor along a needle tract (6).
Certain risk factors increase the chances of needle tract
implantation, including (a) superficial or subcapsular
location of the tumor (7, 8), (b) more needle passes (1, 9),
(c) large needle bore (10), (d) the use of an end-cutting
needle (1, 7), since specimens obtained by end-cutting
needles are often fragmented and lead to greater spillage
of tumor cells along the needle tract than a tru-cut needle,
(e) the absence or a thin layer of surrounding normal liver
parenchyma along the needle tract (1, 9), (f) high-grade
(moderate or poor differentiation) HCC (1, 7, 8, 11), (g)
high serum  -fetoprotein level (8), (h) a tumor larger than
2 cm in diameter enhanced in the early phase on dynamic
CT (11), and (i) patient immunosuppression (12).
Needle Tract Implantation after Percutaneous Biopsy
Despite advanced imaging technologies, HCC imaging
features are frequently nonspecific and indeterminate.
Percutaneous biopsy is the most important nonsurgical
method for histologic diagnosis of focal hepatic lesions,
including HCC with different caliber needles (14- to 22-
gauge) and different needle passes. The frequency of
needle tract implantation of HCC after percutaneous
biopsy is between 0 5.1% (7, 9, 10, 13, 14). In our
institution, percutaneous biopsy was performed by an
abdominal radiologist with the same technique, using
either a 19.5-gauge end-cutting (AutoVac , Angiomed,
Karlsruhe, Germany) or an 18-gauge tru-cut (GUNBIOPSY 
NEEDLE ; Hart, Michigan, MI) needle, with between one
and four needle passes. Needle tract implantation
developed after percutaneous biopsy in nine (0.76%) of
1,182 patients with HCCs during the recent 10-year
period. The implanted tumors were located in the subcuta-
neous fat and intraperitoneum in three, subcutaneous fat
and intercostal muscle in two, intercostal muscle in two,
subcutaneous fat and rectus abdominis muscle in one, and
subcutaneous fat in one. In eight (89%) of those nine
patients, biopsy was performed using an end-cutting needle
(range of needle passes, 2 3; mean, 2.8) (Figs. 1 3), and
in the other one (11%), the biopsy was performed using a
tru-cut needle with four needle passes (Fig. 4). The location
of all primary tumors was supracapsular.
Needle tract implantation is possible when the tumor is
identified on imaging or physical examination in the
perihepatic intraperitoneum, intercostal muscle, abdominal
muscle, subcutaneous fat, or cutaneous tissue along the
pathway of the needle. CT is the preferred imaging
technique for evaluating needle tract implantation and the
liver (7, 9). Although implanted tumors may have linear or
elongated configurations (Fig. 1), they usually show one or
a few, round or oval-shaped enhancing nodules along the
previous needle tract (Fig. 2). The tumors can be located
from the intraperitoneum through the intercostal or
abdominal muscles to the subcutaneous or cutaneous
tissues, with or without a linear arrangement (Figs. 1 4)
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Fig. 1. 65-year-old woman with linear or
elongated configuration of needle tract
implantation after percutaneous biopsy
of subcapsular hepatocellular
carcinoma.
A. Contrast-enhanced CT image
showing 7-cm-diameter, subcapsular
hepatocellular carcinoma (arrows). This
patient underwent percutaneous biopsy
using end-cutting needle.
B. Contrast-enhanced CT image
showing linear soft tissue attenuation
lesion (arrow) seen in subcutaneous fat
layer of right anterolateral chest wall four
months after percutaneous biopsy. Note
lipiodol-laden primary tumor after
transcatheter arterial chemoemboliza-
tion (arrowheads).
AB(7, 9, 11). If the lesions grow, they conglomerate and form
a relatively large mass (Fig. 3). Although the implanted
tumors can reach diameters of 5 cm, they are usually
smaller than 2 cm (7, 9, 13). On contrast-enhanced, triple-
phase CT, the implanted tumors may show hyperattenua-
tion with hypervascularity or isoattenuation relative to the
surrounding structures on the arterial phase. Thereafter,
they show persistent enhancement with high- or iso-attenu-
ation on portal and equilibrium phases, similar to the
typical enhancement pattern (arterial enhancement,
followed by washout) of HCC in the liver compared to
hepatic parenchymal enhancement (Fig. 4) (7, 9).
However, the contrast enhancement pattern may be
influenced by the size of the implanted tumors and the
characteristics of the primary HCC (9). Different enhance-
ment patterns of implanted tumors and HCCs in the liver
may occur due to different blood supplies between the
liver and the surrounding tissue where the implanted
tumor is located (7).
The growth rate of needle tract implantation after biopsy
varies depending on the initial number of inoculated tumor
cells and the doubling time of the tumor, as well as the
microenvironment surrounding the implanted tumors. The
doubling time of the implanted tumors is between 22 and
Chang et al.
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Fig. 2. 50-year-old man with needle tract
implantation with round or oval-shaped
configuration and linear arrangement
after percutaneous hepatocellular
carcinoma biopsy.
A. Contrast-enhanced CT image
showing small, round nodule (arrow) in
peritoneal cavity along previous needle
tract three months after percutaneous
biopsy using end-cutting needle. Note
lipiodol-laden primary tumor
(arrowhead) after transcatheter arterial
chemoembolization.
B. Follow-up CT image showing two
round nodules with rapid growth
(arrows) in peritoneal cavity and
subcutaneous fat layer six months after
percutaneous biopsy.
AB
Fig. 3. 66-year-old woman with needle
tract implantation with large conglomera-
tion around rib after percutaneous
hepatocellular carcinoma biopsy,
followed by right hepatic lobectomy.
A. Contrast-enhanced CT image
showing isoattenuation nodules (arrows)
relative to intercostal muscles in
intercostal muscles and subcutaneous
fat layer five months after percutaneous
biopsy using end-cutting needle.
B. Follow-up CT image showing
conglomerated nodules (arrows) with
increased size nine months after
percutaneous biopsy.
AB415 days (mean, 112 days) (7), which is comparable to that
of HCC in the liver, or 27 to 605 days (range of means,
102 204 days) (15, 16). The time intervals between
biopsy and emergence of needle tract implantation ranged
from three weeks to six years (14). In our institution, the
time from biopsy to diagnosis of needle tract implantation
was four to 21 months (mean, 9 months).
Needle Tract Implantation after PEIT
Percutaneous ethanol injection therapy is a low risk,
well-established treatment for small HCCs, but can lead to
needle tract implantation (11, 12, 17). Although alcohol
was thought to sterilize the needle tract and prevent
implantation after PEIT (12), the frequency of needle tract
implantation is between 0.2% 1.4% (11, 17). PEIT may
increase the risk of needle tract implantation compared
with biopsy alone because PEIT requires multiple needle
punctures over an extended period, despite the advantage
of a smaller caliber needle (21 22 gauge) (11). In our
institution, PEIT was performed by one of four experi-
enced abdominal radiologists with the same technique. The
needles used for PEIT were 21-gauge needles with three
side holes and no end hole (PEIT Needle; Hakko, Tokyo).
Tumor diameter dictated the amount of alcohol injected: 8
ml for tumors 1 cm in diameter, 15 ml for tumors 2 cm in
diameter, and 25 ml for tumors 3 cm in diameter.
Injections were performed two or three times a week,
depending on patient tolerance, until the total amount of
alcohol injected reached the intended volume. Three to
eight milliliters of ethanol were administered to each
tumor until the ethanol distributed throughout a tumor or
until ethanol leakage from a tumor was observed. There
was one case (1.9%) of needle tract implantation in the
subcutaneous fat among 53 patients who underwent
conventional, multisession PEIT (mean session per tumor,
3.7) during the recent 10-year period (Fig. 5). Multiple
needle punctures might cause needle tract implantation, as
would failing to perform preventive ablation of the needle
tract, although the tumor was centrally located. There are
no reports of growth rate for these tumors, but Ishii et al.
(11) reported that the time intervals between PEIT and
diagnosis of needle tract implantation ranged from 10 to
46 months (mean, 21 months).
The imaging findings of needle tract implantation after
PEIT were similar to percutaneous biopsy and previous
reports (Fig. 5) (11, 12, 17).
Needle Tract Implantation after RF Ablation
Radiofrequency ablation is a safe and effective treatment
for malignant tumors, especially HCCs. The goal of RF
ablation is to kill the index tumor as well as an ablative
margin, a peripheral margin of 0.5 to 1.0 cm of normal
hepatic parenchyma surrounding the tumor. Each ablation
requires exact placement of the electrode tip in the tumor
and, when necessary, multiple overlapping ablations are
performed according to the morphology of the tumor (18).
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Fig. 4. 63-year-old man with needle tract implantation after percutaneous biopsy using tru-cut needle.
A. Contrast-enhanced CT image obtained on arterial phase showing well-demarcated, hyperattenuating hypervascular nodule (arrow)
relative to intercostal muscles in right chest wall.
B, C. Contrast-enhanced CT images obtained on portal (B) and equilibrium (C) phases showing nodule (arrows) with persistent
enhancement and hyperattenuation relative to intercostal muscles in right chest wall. Note subcapsular lipiodol-laden mass (arrowhead
in B).
ABCRF ablation uses 14- to 17-gauge needles, and the
frequency of needle tract implantation after RF ablation
ranges from 0% to 4.4% (19, 20), although a rate of
12.5% has been reported by one center (8). In our institu-
tion, RF ablation was performed by one of four experi-
enced abdominal radiologists with the same technique.
From April 1999 to June 2000, 15-gauge multitined
expandable electrodes (model 500 series and 1,500 series,
Radiofrequency Interstitial Thermal Ablation Medical
System, Mountain View, CA or RF 2000 system,
RadioTherapeutics Corporation, Mountain View, CA)
were used exclusively. In July 2000, we began to use 17-
gauge internally cooled electrodes (Cool-tip, Valleylab,
Boulder, CO). All patients were treated under intravenous
conscious sedation and local anesthesia. We usually prefer
the internally cooled electrode for the treatment of tumors
near the large, central vessels close to the hepatic hilum
and near the gallbladder, colon, and stomach that could be
damaged by the fully deployed tines of the multitined
expandable electrode. Whenever possible, multiple
overlapping ablations (2 6 overlapping ablations; mean,
2.6) were performed for tumors larger than 2.5 cm in
diameter. During the recent 10-year period, five cases
(1.2%) of needle tract implantation were detected among
414 patients who underwent percutaneous RF ablation
without percutaneous biopsy (Fig. 6). Of these, four
patients were treated with a multitined expandable
electrode and one patient was treated with an internally
cooled electrode. The primary tumors were all subcapsular,
and the implanted tumors were found in the intraperi-
toneum in two, intraperitoneum and intercostal muscle in
two, and subcutaneous fat in one. 
The ablation of the needle tract after RF ablation, use of
an internally cooled electrode, and smaller treatment
sessions could reduce needle tract implantation compared
with PEIT. One study (8) reported a higher incidence
(12.5%) of needle tract implantation using an internally
cooled electrode, with subcapsular primary tumors and no
ablation of the needle tract. However, no reports address
whether multitined expandable electrodes or internally-
cooled electrodes have a higher incidence of needle tract
implantation (8). We routinely perform needle tract
ablation and use an internally cooled electrode, which may
reduce the incidence of needle tract implantation, and
could explain our lower incidence than seen in that report
(8). The imaging findings of needle tract implantation after
percutaneous RF ablation were similar to percutaneous
biopsy and PEIT (Fig. 6), as well as previous reports (8,
19).
Needle tract implantation after percutaneous RF ablation
would presumably have the same growth profile as
percutaneous biopsy and PEIT. Llovet et al. (8) reported
that the time intervals between RF ablation and diagnosis
of needle tract implantation ranged from four to 18 months
Chang et al.
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Fig. 5. 89-year-old man with needle tract implantation after five times of percutaneous ethanol injection therapy for centrally-located
hepatocellular carcinoma.
A. Contrast-enhanced CT image obtained three months after last percutaneous ethanol injection therapy in right liver shows small tumor
(arrow) in subcutaneous fat layer.
B, C. Follow-up CT images obtained on arterial (B) and equilibrium (C) phases 51 months after percutaneous ethanol injection therapy
showing size increase of implanted tumor (arrows) in subcutaneous fat layer. Imaging findings were similar to needle tract implantation
after percutaneous biopsy.
ABC(mean, 8.8 months). In our institution, the time interval
between RF ablation and diagnosis of needle tract implan-
tation ranged from four to 13 months (mean, 8.8 months).
Minimization of Needle Tract Implantation
Based on our 10-year experience, percutaneous needle
biopsy should be performed only when necessary, as for
determining if a lesion is benign or if pathologic confirma-
tion is necessary prior to nonsurgical therapies, including
transcatheter arterial chemoembolization, PEIT, RF
ablation, or chemotherapy.
The most important principles for avoiding needle tract
implantation are to minimize the number of punctures, the
frequency of repositioning the needles, and to traverse a
sufficient portion of normal hepatic parenchyma, particu-
larly in subcapsular tumors. In percutaneous biopsy,
reducing piston-like movement of the needle, absorbing
debris using negative pressure, or using a tru-cut needle
can diminish the fragmentation of malignant tissue and
minimize spillage of tumor cells along the needle tract. A
single pass using a larger bore needle may be better than
multiple passes using smaller bore needles (21).
Using larger volumes of alcohol during each needle
placement for PEIT may decrease the risk of needle tract
implantation because of the sterilizing effect of alcohol
along the needle tract and fewer punctures (12). Ablation
of the needle tract may alo help minimize needle tract
implantation (19). When using the internally cooled
electrode for RF ablation, sufficient RF energy should be
maintained for minimizing needle tract implantation by
viable cancer cells adhered to the electrode after cooling.
However, we learned that needle tract implantation still
occurs with some frequency, necessitating careful follow-
up of patients, particularly when tumor markers increase in
spite of well-controlled hepatic disease.
Management of Needle Tract Implantation
Although needle tract implantation does not usually
affect patient survival (7, 9, 11 14, 17), it may change a
potentially curable HCC into an untreatable situation via
tumor dissemination to other organs or the peritoneum
(22). Therefore, minimizing needle tract implantation is
important, as is detection early during tumor growth,
which can then be treated successfully by surgical excision
(7, 9). Twelve of 15 patients with localized needle tract
implantation in our institution were treated with surgical
excision. Implanted tumors were not treated in the remain-
ing three patients because of recurrent HCCs in the liver
and/or a poor medical condition. Needle tract implantation
can alo be managed by ablation, embolization, or radiation
therapy (10 12, 14, 17).
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Fig. 6. 72-year-old man with needle tract implantation after percutaneous radiofrequency ablation of hepatocellular carcinoma, with
history of transcatheter arterial chemoembolization.
A-C. Contrast-enhanced CT images obtained on arterial (A), portal (B), and equilibrium (C) phases 13 months after percutaneous
radiofrequency ablation using multitined expandable electrode for viable tumor within partial lipiodol-laden mass. Images show two small
enhancing lesions (arrows) involving intercostal muscles along previous needle tract. Imaging findings were similar to needle tract
implantation after biopsy and percutaneous ethanol injection therapy. Note subcapsular lipiodol-laden mass (arrowhead) with no residual
viable tumor after percutaneous radiofrequency ablation.
ABCCONCLUSION
Percutaneous interventional procedures such as biopsy,
PEIT, and RF ablation are useful in managing HCCs.
Although uncommon, needle tract implantation occurs
with an incidence that is not negligible, ranging from
0.76% to 1.9% in our institution. All implantations show
similar imaging findings, appearing as one or a few, round
or oval-shaped enhancing nodules along the previous
needle tract on CT, from the intraperitoneum through the
intercostal or abdominal muscles to the subcutaneous or
cutaneous tissues. During intervention procedures, radiolo-
gists should minimize the number of punctures and the
frequency of needle repositioning, as well as traverse a
sufficient portion of normal hepatic parenchyma, especially
for subcapsular tumors, to minimize needle tract implanta-
tion. The use of a tru-cut needle for biopsy, larger volumes
of alcohol during needle placement for PEIT, and an
ablation of the needle tract during RF ablation may help
minimize needle tract implantation. During follow-up,
radiologists should pay attention to the presence of
implanted tumors along the needle tract for early diagno-
sis.
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